See more : Mobiv Acquisition Corp (MOBV) Income Statement Analysis – Financial Results
Complete financial analysis of WPD Pharmaceuticals Inc. (WBIO.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of WPD Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Green Mountain Development Corp. (GMND) Income Statement Analysis – Financial Results
- LAN & SPAR INVEST (LSIB60.CO) Income Statement Analysis – Financial Results
- Jauss Polymers Limited (JAUSPOL.BO) Income Statement Analysis – Financial Results
- TOD’S S.p.A. (TODGF) Income Statement Analysis – Financial Results
- Sparinvest Globale Fokusaktier KL (SPIGFA.CO) Income Statement Analysis – Financial Results
WPD Pharmaceuticals Inc. (WBIO.CN)
About WPD Pharmaceuticals Inc.
WPD Pharmaceuticals Inc. engages in the research and development of medicinal products in the fields of oncology and infectious diseases. Its drug development pipeline includes WPD101 to treat brain cancers, including glioblastoma that is in the pre-clinical trial; WPD102 to treat Uval Melanoma, which is in the pre-clinical trial; Berubicin for the treatment of glioblastoma that us in phase 1 clinical trial; and WP1066 to treat central nervous system tumors, pancreatic cancer, and ocular tumors, which is in phase 1 clinical trial. The company's drug development pipeline also includes WP1732 for the treatment of pancreatic cancer; WP1220 to treat cutaneous T-cell lymphoma; WPD103 for the treatment of glioblastoma multiforme that is in the pre-clinical trial; and Annamycin to treat acute myeloid leukemia (AML) and metastasis to lungs, which is in Phase I/II clinical trials in AML. WPD Pharmaceuticals Inc. is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 24.44K | 290.22K | 391.77K | 111.10 | 0.00 | 0.00 | 0.00 | 0.00 | 233.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -24.44K | -290.22K | -391.77K | -111.10 | 0.00 | 0.00 | 0.00 | 0.00 | -233.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | -4.30K | 463.61K | 97.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 227.25K | 2.21M | 4.37M | 1.69M | 13.07M | 808.04K | 422.87K | 198.84K | 19.21K | 53.60K | 115.98K | 131.37K | 184.64K | 171.91K | 341.78K | 160.15K | 0.00 | 0.00 |
| Selling & Marketing | 41.66K | 2.28M | 73.79K | 392.05K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 813.00 | 0.00 | 17.84K | 13.51K | 3.76K | 0.00 | 0.00 |
| SG&A | 268.91K | 2.29M | 5.98M | 7.53M | 13.07M | 808.04K | 422.87K | 198.84K | 19.21K | 53.60K | 115.98K | 132.18K | 184.64K | 189.75K | 355.30K | 163.91K | 657.00 | 1.20K |
| Other Expenses | 0.00 | -18.78K | -70.28K | -76.38K | 100.73K | 19.17K | 2.33K | 0.00 | 0.00 | 233.00 | 444.00 | 634.00 | 710.00 | -191.60K | -27.00K | 13.23K | 0.00 | 0.00 |
| Operating Expenses | 268.91K | 2.30M | 6.04M | 8.07M | 13.18M | 808.04K | 422.87K | 198.84K | 19.21K | 53.84K | 116.42K | 132.81K | 185.35K | -1.85K | 328.30K | 177.14K | 657.00 | 1.20K |
| Cost & Expenses | 268.91K | 2.33M | 6.33M | 8.46M | 13.18M | 808.04K | 422.87K | 198.84K | 19.21K | 53.84K | 116.42K | 132.81K | 185.35K | -1.85K | 328.30K | 177.14K | 657.00 | 1.20K |
| Interest Income | 0.00 | 0.00 | 0.00 | 15.96 | 60.66 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 833.00 | 2.90K | 3.85K | 1.88K | 8.58K | 0.00 | 0.00 |
| Interest Expense | 39.65K | 167.52K | 88.54K | 21.73K | 60.66K | 2.17K | 46.11K | 4.66K | 2.74K | 4.88K | 302.00 | 483.00 | 480.00 | 1.85K | 440.00 | 547.00 | 0.00 | -1.20K |
| Depreciation & Amortization | 332.00 | 24.44K | 290.22K | 391.77K | 100.73K | 9.60K | 2.33K | -641.00 | -118.00 | 233.00 | 444.00 | 634.00 | 710.00 | 337.00 | 25.00K | -547.00 | 0.00 | 0.00 |
| EBITDA | -40.43K | 4.05M | -5.24M | -7.11M | -3.39M | -788.87K | -377.28K | -199.48K | -19.33K | -54.40K | -116.28K | -114.51K | -182.22K | -275.28K | -303.30K | -169.11K | -657.00 | -1.20K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -268.91K | -2.33M | -6.33M | -8.46M | -12.07M | -808.04K | -422.87K | -198.84K | -19.21K | -54.05K | -116.42K | -131.98K | -182.45K | 1.85K | -328.30K | -176.60K | -657.00 | -1.20K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 188.83K | 6.19M | 708.61K | 935.77K | 459.56K | 28.60K | -513.00 | -5.30K | -2.86K | -5.68K | -302.00 | 16.84K | 2.90K | 2.01K | -25.00K | 7.49K | 0.00 | 0.00 |
| Income Before Tax | -80.08K | 3.86M | -5.62M | -7.52M | -11.61M | -779.44K | -423.38K | -204.13K | -22.07K | -59.73K | -116.72K | -115.14K | -182.93K | 0.00 | -353.30K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 4.00 | 2.00 | 0.00 | 1.16M | -30.77K | -45.60K | 641.00 | 118.00 | 802.00 | 302.00 | -17.32K | 480.00 | 188.08K | 23.12K | -8.58K | 20.00 | 1.20K |
| Net Income | -80.08K | 3.86M | -5.62M | -7.52M | -12.78M | -779.44K | -423.38K | -204.13K | -22.07K | -59.73K | -116.72K | -115.14K | -182.93K | -188.08K | -351.86K | -169.11K | -677.00 | -1.20K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.03 | -0.05 | -0.07 | -3.74 | -0.04 | -0.07 | -0.07 | -0.01 | -0.02 | -0.04 | -0.04 | -0.07 | -0.07 | -0.15 | -0.09 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.03 | -0.05 | -0.07 | -3.74 | -0.04 | -0.07 | -0.07 | -0.01 | -0.02 | -0.04 | -0.04 | -0.07 | -0.07 | -0.15 | -0.09 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 113.59M | 113.44M | 113.44M | 113.13M | 3.42M | 21.42M | 6.03M | 2.73M | 2.73M | 2.73M | 2.72M | 2.72M | 2.72M | 2.71M | 2.30M | 1.99M | 840.00K | 1.59M |
| Weighted Avg Shares Out (Dil) | 113.44M | 113.44M | 113.44M | 113.13M | 3.42M | 21.42M | 6.03M | 2.73M | 2.73M | 2.73M | 2.72M | 2.72M | 2.72M | 2.71M | 2.30M | 1.99M | 840.00K | 1.59M |
Source: https://incomestatements.info
Category: Stock Reports